Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at D. Boral Capital

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $13.00 price objective on the stock.

Separately, HC Wainwright lifted their price objective on shares of Enlivex Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, March 24th.

Enlivex Therapeutics Stock Down 3.9 %

Shares of ENLV traded down $0.04 during trading hours on Thursday, reaching $0.97. 12,946 shares of the company traded hands, compared to its average volume of 154,068. The business has a fifty day moving average price of $1.08 and a 200-day moving average price of $1.23. Enlivex Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.59. The stock has a market capitalization of $20.79 million, a P/E ratio of -0.99 and a beta of 1.11.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.07). As a group, research analysts predict that Enlivex Therapeutics will post -0.7 EPS for the current fiscal year.

Institutional Trading of Enlivex Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in shares of Enlivex Therapeutics during the 4th quarter valued at about $742,000. Renaissance Technologies LLC increased its position in shares of Enlivex Therapeutics by 112.6% in the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after buying an additional 84,203 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new position in shares of Enlivex Therapeutics during the 4th quarter worth approximately $26,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.